Dimitrios Kandylas

Dimitrios Kandylas

Counsel

Expertise

  • Corporate
  • Corporate Finance & Securities
  • Debt & Finance
  • Capital Markets & Securities

WSG Practice Industries

Activity

Lowenstein Sandler LLP
New Jersey, U.S.A.

Profile

Dimitrios is a problem solver, valued by his clients for his creativity and ability to provide clear, practical advice when confronted with difficult issues.

Dimitrios represents clients in a variety of industries, but largely focuses on the representation of pharmaceutical, biotech, and medical device companies in complex transactional and regulatory matters. Drawing on his experience with a wide range of commercial transactions–including the negotiation of acquisitions, divestitures, development agreements, strategic alliances, services agreements, licensing transactions, commercial rebate and discount arrangements, supply and distribution agreements, debt arrangements, and other commercial matters–he provides responsive service and strategic, individualized solutions.

Prior to becoming a lawyer, Dimitrios completed an MBA with a concentration in pharmaceutical management and finance. He was a valued member of the Leadership Development Program at Roche Laboratories, where he focused on market access contracting across a variety of customer segments.

Bar Admissions

    New York
    New Jersey

Education

Rutgers Law School (J.D. 2011), summa cum laude; Order of the Coif; Saul Tischler Memorial Prize (awarded for the highest GPA in the graduating class); A. Harry Moore Prize; Frank and Marilyn Askin Award for Excellence in Clinical Studies
Rutgers University School of Business (M.B.A. 2008), Beta Gamma Sigma International Honor Society; Pharmaceutical Industry Scholar
Binghamton University (B.A. 2001), magna cum laude
Areas of Practice

Capital Markets & Securities | Corporate | Corporate Finance & Securities | Debt & Finance | Debt Finance | Life Sciences | Mergers & Acquisitions | Private Equity | Transactions & Advisory Group

Blogs

Capital Markets Litigation
Lowenstein Sandler LLP 

Litigation News for the Global Financial Community